AYUR-VEDA BIO-DEVELOPMENT LIMITED COMPANY
Update:2026/01/07
Industries
Main Industry
Biotechnology
Main Product/Service
OBI Pharma’s product and technology portfolio focuses on antibody-drug conjugates (ADCs) and enabling platforms. Core proprietary technologies include GlycOBI® glycan-conjugation platform, EndoSymeOBI®, ThiOBI®, HYPrOBI™, which enable plug-and-play compat
Founded Year
2018
Unified Business No.
50775252
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
OBI Pharma, Inc., founded in 2002 with its headquarters and R&D center in Taiwan, and subsidiaries in the United States and Australia, is a global clinical-stage oncology company. The company focuses on innovative cancer therapies, aiming to develop first